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Available online 1 July 2014Glycan-based suspension array (SGA) is an “in-house” developed multi-target immunoassay,
employing commercially available fluorescent microbeads as a solid support for unique
chemically synthesized glycopolymers which capture naturally occurring human anti-glycan
antibodies. SGA is a sensitive and reliable tool for the high-throughput screening of anti-glycan
antibody alterations characteristic for a vast number of human diseases including cancer.
However, unspecific background binding, for instance binding of non-target antibodies, is a
common obstacle in such immunoassays. In an attempt to reduce unspecific background
binding of serum (or plasma) antibodies, we prepared glycosylated microbeads modified with
linear poly(ethylene glycols) (PEGs) of different lengths. We compared several kinds of PEG
modifications: (a) partial side-chain substitution of glycopolymers by PEGs of different
lengths, (b) end-point addition of biotin-linked PEGs to glycopolymer-coupled beads, and
(c) linking of heterobifunctional PEGs to the bead surface prior to glycopolymer immobiliza-
tion. Among the various modifications investigated, the direct modification of the bead surface
with linear heterobifunctional PEGs, consisting of 23- and 60 PEG-units significantly reduced
the background binding. The end-point addition of biotin-linked PEGs, especially in the case of
PEG consisting from 50 PEG-units, helped to repel non-target binding caused by endogenous
biotin. We observed unspecific binding predominantly for antibodies of IgG but of IgM class.
The novel design of fluorescent microbeads allows the detection of human anti-glycan
antibodies with increased specificity and opens new horizons for practical application of SGA
as a diagnostic tool.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Keywords:
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-nd/3 .0/) .1. Introduction
Ovarian cancer is the fifth most common cause of death
from all cancers occurring in women and the leading cause
of death from gynecological malignancies (Ozols, 2006).
This poor outcome (overall survival of less than 20%)
results from the lack of early disease-specific symptoms
and reliable tools (e.g. tumor markers) for early diagnosis,i s an open access art ic le under the CC BY-NC-ND license
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limited understanding of the early-initiating events and
early stages of ovarian cancer development.
For the search and the identification of sensitive and
ovarian cancer-specific tumor biomarkers we have previ-
ously developed “in-house” and then validated a multiplex
suspension array specifically designed for the high through-
put detection and profiling of anti-glycan antibodies natu-
rally occurring in human blood serum/plasma for diagnostic
purposes (Pochechueva et al., 2011a).
Our first version of the SGA employed chemically synthe-
sized glycans in the form of end-biotinylated polyacrylamide
conjugates (Chinarev et al., 2010) coupled to commercially
available fluorescence-labeledmicrobeads, allowing the specific
multivalent binding of anti-glycan antibodies or lectins to
the immobilized glycopolymers. The set of glycans included
P1 (Galα1–4Galβ1–4GlcNacβ), a trisaccharide which we
have previously identified using PGA as significantly associ-
ated with ovarian cancer (Jacob et al., 2012). We found that
the SGA, when compared to the PGA, exhibited a similar or,
in some cases, even higher sensitivity and specificity in the
detection of plasma anti-glycan antibodies (Pochechueva et
al., 2011b; Jacob et al., 2012), which is one benefit of SGA.
The other benefits of SGA are the opportunity to assess multi-
ple analytes in a single sample, the wide dynamic range, the
feasibility of the assay reconfiguration, and the minuteScheme 1. Schematic presentation of the routine “sandwich construct” (A), the thre
of antibody-bead interactions. Specific (filled turquoise rectangles) binding and un
shown. Prevention of unspecific binding is highlighted by a red-framed transparenconsumption of glycans and glycan-binding proteins, making
SGA an attractive tool for biomedical and diagnostic
applications.
A crucial step for the quality/performance of the SGA is
the immobilization of the glycoconjugates to the fluorescent
microbeads. In our previous study (Pochechueva et al., 2011a)
we have compared several approaches for the immobilization,
and found that the multi-step coupling procedure, i.e. the
anchoring of streptavidin to the beads and the subsequent
attachment of the polyacrylamide-based glycopolymer end-
capped with single biotin, was the most appropriate strategy
for the specific binding of serum/plasma-derived antibodies.
This “sandwich construct” (Scheme 1A) is rather complex but
stable and well-suited for highly sensitive detection of specific
interactions between glycans and glycan-binding antibodies
(Pochechueva et al., 2011a,b).
However, unspecific or non-target interactions between
analytes and glycopolymers (and even microbeads) can
naturally occur in immunoassays such as SGA due to the high
complexity of the analyte sample of interest (human serum/
plasma or other body fluids) and the characteristics of the
employed microbeads. For instance, in addition to binding to
glycans, serum/plasma antibodies may also recognize other
sites on the surface of beads or even adhere to beads in a
purely unspecific way. Due to the large heterogenic interface
antibodies may bind to unmodified portions of the beade kinds of PEG-modified glycobead (B–D) preparations, and the various types
specific (filled red rectangles) binding of antibodies to glycan moieties are
t rectangle.
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and polyacrylamide, molecules in a non-immunological
fashion, i.e. via hydrophobic or electrostatic interactions.
So-called heterophilic antibodies (Kricka, 1999; Martins et
al., 2006; Waterboer et al., 2006) may be engaged in the fine
regulation of the immune system and are believed to bind,
though with low affinity, to a variety of antigens such as
self-antigens or even purely synthetic molecules. Unspecific
interactions, in particular those arising by heterophilic
antibodies (Levinson and Miller, 2002; Bjerner et al., 2005;
Preissner et al., 2005), are likely to increase the background
signal and to fail in the detection of low-affinity interactions
between glycans and anti-glycan antibodies. This negatively
affects the SGA outcome (specificity and sensitivity) and
complicates the interpretation of the SGA results, eventually
producing false-positive and negative or over- or understat-
ed results and therefore compromising the reliability of SGA.
Avoiding or at least minimizing unspecific interactions/
binding of antibodies is considered essential for the design of
glyco-analysis tools. Two common strategies can be utilized
(Ratner, 2005). (i) The analytical platform (e.g. bead
surface) is covered with a dense monolayer of antigens or
glycans. However, antibodies may be incapable of tight
binding to target glycans constituting such monolayers due
to the suboptimal surface density of glycan residues and
to the length of their bonds to the surface. (ii) Parts of the
analytical platform remain unoccupied by the glycans and
are blocked (masked) by a detergent, a protein or a synthetic
polymer such as poly(ethylene glycol) (PEG), a linear or
branched polyether terminated with hydroxyl groups. This
strategy is based on the protein-repelling effect of PEG due
to the low free energy at PEG–water interface, incapability of
hydrogen bonding or electrochemical interaction of PEG with
proteins, and to the highmobility of PEG chains (Kingshott and
Griesser, 1999). The particular characteristics of PEG, including
its water like-structure, absence of charges, resistance to
protein adsorption, variation inmolecularweight, size (length)
and shape, and low immunogenicity make PEG not only
suitable for biomedical and therapeutic applications (Desai
and Hubbell, 1991; Prime and Whitesides, 1991; Bergstrom et
al., 1992; Roberts et al., 2002; Caliceti and Veronese, 2003;
Larsson et al., 2007; Fishburn, 2008;Wattendorf et al., 2008a,b;
Jain and Nahar, 2010; Jokerst et al., 2011), but also ideal
molecules in the design of SGA and related tools.
In the latter context, bifunctional PEG tags were recently
used as protein-repelling spacers for glycan primers. These
glycoPEG tags were conjugated to latex fluorescent beads and
these glycoPEG-functionalized beads were shown to bind to a
lectin array with higher sensitivity and selectivity than
glycan beads without PEG tag (Etxebarria et al., 2013). PEG
linking appears to be a suitable strategy, although it can in
some circumstances (PEG of inappropriate length, density or
orientation) also cause spatial masking (steric interference)
of specific antigen epitopes and therefore result in the loss of
binding potency (Fishburn, 2008).
The main objective of the present study was the opti-
mization of our current/first version of SGA through the
reduction/minimization of unspecific (background) anti-
body binding. We explored (i) how the modification of
the beads with linear PEGs of different lengths can
influence both specific and unspecific antibody bindingand (ii) which of these modifications reduce unspecific
binding. We demonstrate that unspecific antibody binding
was significantly reduced by the direct modification of the
bead surface with linear heterobifunctional PEG consisting
of 23- and 60 PEG-units and by avoiding the employment of
IgG-class antibodies.
2. Materials and methods
2.1. Antibodies
The following antibodies from the indicated suppliers
were used: anti-P1 human monoclonal IgM antibody (clone
P3NIL100, Immucor Gamma GmbH, Rödemark, Germany,
dilutions used: 1/200; 1/500; 1/1000; 1/2000; 1/5000;
and 1/10,000); anti-Gb3 (CD77, Pk) murine IgG2b (clone
BGR23, Seikagaki Biobusiness Corp., Tokyo, Japan, dilution
of 1/100); anti-Gb3 (CD77, Pk) rat monoclonal IgM (AbD
Serotec, Oxford, England, dilution of 1/100); biotin mouse
anti-rat IgM (BD Pharmingen™, BD Biosciences, Allschwil,
Switzerland, dilution of 1/1000); R-phycoerythrin
(R-PE)-streptavidin (LubioScience GmbH, Luzern, Switzer-
land, dilution of 1/200); goat anti-human R-PE conjugated
Ig (H + L), IgM or IgG antibodies (dilution of 1/1000) and
goat anti-mouse Ig (H + L) antibodies (dilution of 1/1000,
Southern Biotechnology Associates, Inc., Birmingham, AL,
USA).
2.2. Human plasma samples
Blood samples were collected prospectively from healthy
women at the Department of Gynecology, University Hospital
Zurich after informed consent was granted (ethical approval to
V.H.S., SPUK Canton of Zurich, Switzerland). Specimens were
processed and stored as described previously (Pochechueva et
al., 2011b; Jacob et al., 2012). Human plasma samples were
used in all the experiments in the dilution of 1/40, as described
previously (Pochechueva et al., 2011a). Plasma samples from
healthy donors of blood groups A, B and O (five donors each
group) were pooled in equal volumes and used similarly to
individual plasma samples.
2.3. Glycopolymers with end-biotin group
The glycopolymers, Glyc(20)–PAA–biot1, Glyc(20)–PAA–
PEG4(80)–biot1, and Glyc(20)–PAA–PEGm(5)–biot1, used for
coupling to fluorescent beads were produced in-house as
previously described (Chinarev et al., 2010); their chemical
structures are presented in Fig. 1. The glycopolymers are
composed of a polyacrylamide carrier (PAA, number of the
average polymerization degree, n = 220) provided with end
biotin groups and side-pendant Glyc residues, either Galα1–4-
Galβ1–4GlcNAcβ– (referred to as P1) or Galα1–3(Fucα1–2)
Galβ– (referred to as Btri) that are statistically distributed along
the polymer backbone. The content of monomer units with
glycan substitution is 20 mol%. Non-glycosylated monomer
units are substituted either with an ethanolamine residue for
the regular Glyc(20)–PAA–biot1 orwith an tetraethylene glycol
residue for Glyc(20)–PAA–PEG4(80)–biot1. For Glyc(20)–PAA–
PEGm(5)–biot1, 5 mol% of non-glycosylatedmonomer units are
conjugated with long PEG chains, m ~ 50 (MW ~ 2.2 kDa) or
Fig. 1. Chemical structure of the regular glycopolymer (top) and its newly synthesized PEGylated analogs (bottom).
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substituted with ethanolamine.
2.4. PEGs used for glycopolymer and microbead modiﬁcations
Biot-PEGm were produced in-house by ligation of biotin–
NH(CH2)5COONp (Lectinity Holdings, Moscow, Russia) with
the PEG-amines, NH2CH2CH2CH2(OCH2CH2)mOCH3, m ~ 50
(MW ~ 2.5 kDa) or 280 (MW ~ 12.5 kDa), which were pur-
chased (NDF Corp, Tokyo, Japan). The chemical structure of
biot-PEGm is presented in Fig. 2A.
Hetero-bifunctional PEGs (biot-PEGm-NH2) were purchased
(Iris Biotech GmbH, Marktredwitz, Germany). Biot-PEG23-NH2
was the individual compound (MW = 1300), whereas biot-
PEG60-NH2 was a polymer with MW ~ 3.0 kDa (Fig. 2B).
2.5. Modiﬁcation of ﬂuorescent microbeads
2.5.1. The regular coupling procedure
Biotinylated glycopolymers were coupled to fluorescent
Bio-Plex Pro™ magnetic COOH beads of 6.5 μm diameter
with distinct spectral “addresses” (Bio-Rad Laboratories Inc.,
Hercules, CA, USA). Each bead's region was embedded with a
precise ratio of red and infrared fluorescent dyes allowing its
identification using a Bio-Plex 200 suspension array system
(Bio-Rad Laboratories Inc., Hercules, CA, USA). Coupling ofbiotinylated glycopolymers was accomplished similarly to
the procedure developed for non-magnetic Bio-Plex carbox-
ylated beads (Pochechueva et al., 2011b). Briefly, the stock
vial of microspheres (1.25 × 107 microspheres/ml) was vig-
orously vortexed for 30 s and sonicated for 15 s in a water
bath prior to its use. The tube with bead suspension (1 scale
reaction: 100 μl; 1.25 × 106 microspheres) was placed into a
magnetic separator (DynaMag™-2, Life Technologies, Zug,
Switzerland) for 30–60 s and the supernatant carefully
removed. The pellet was resuspended in bead wash buffer
(100 μl; Bio-Plex amine coupling kit, Bio-Rad Laboratories
Inc., Hercules, CA, USA) by vortexing and sonication, and
applied for magnetic separation as described above. After
gentle removal of supernatant, the pellet was resuspended in
80 μl of bead activation buffer (Bio-Plex amine coupling kit,
Bio-Rad Laboratories Inc., Hercules, CA, USA), vortexed and
sonicated. Sulfo-N-hydroxysuccinimide sodium salt (S-NHS)
and 1-ethyl-3-[3,3-dimethylaminopropyl]carbodiimide hy-
drochloride (EDC; Pierce Biotechnology, Rockford, IL, USA,
both 50 mg/ml in activation buffer) were prepared immedi-
ately prior to use, and 10 μl of each solution was added to the
bead suspension, followed by vortexing for 30 s. Beads were
agitated in the dark on a rotator at room temperature for
20 min. The activated beads were applied for magnetic
separation and supernatant was removed. The pellet was
resuspended in 150 μl biotin-solution (0.1 MNaHCO3, pH 8.3,
Fig. 2. Biotinylated PEGs (biot-PEGm, where m = 50 or 280) (A) and heterobifunctional PEGs (biot-PEGm-NH2, hereafter PEG23 and PEG50) (B) used for coupling
to fluorescent beads.
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Holdings, Moscow, Russia) and agitated in the dark on a
rotator at room temperature for 2 h. Obtained biotinylated
beads were pelleted by magnetic separation and resuspended
in 150 μl of 50 mM ethanolamine (Sigma-Aldrich Chemie
GmbH, Buchs, Switzerland) in 0.1 MNaHCO3, pH 9.0 to quench
unbound activated groups. Beads were agitated in the dark on
a rotator at room temperature for 30 min. After magnetic
separation the pellet waswashed twicewith 500 μl PBS, pH 7.4
and resuspended in streptavidin-solution (400 pmol strep-
tavidin in 150 μl PBS; Bio-Rad Laboratories Inc., Hercules, CA,
USA). Suspended beads were vortexed and agitated in the
dark on a rotator at room temperature for 2 h. Beads were
washed twice with 500 μl PBS using a magnetic separator.
Glyc–PAA–biot1 solutions, regular (Chinarev et al., 2010), or
PEG-modified (20 pmol per 1 scale coupling reaction in
150 μl PBS, for details see (Pochechueva et al., 2011a,b))
were added to the reaction tubes with streptavidin-coated
beads. The mixture was protected from light and agitated on
a rotator at room temperature for 6 h or overnight at 4 °C.
Modified microspheres were applied to a magnetic separa-
tor, supernatant was removed and beads were washed twice
with 500 μl of bead storage buffer (Bio-Rad Laboratories Inc.,
Hercules, CA, USA). Beads were resuspended in 100 μl ofbead storage buffer and concentration determined using a
hemocytometer (Roth AG, Karlsruhe, Germany) before
storing at 4 °C, protected from light.2.5.2. Coupling of the biotinylated PEGs
An excess of biot-PEGm (m = 50 or 280) was taken to
saturate the binding sites of streptavidin, which still remain
vacant after immobilization of biotinylated glycopolymer on
beads. Namely, 1 μl of 1 mg/ml solution of biot-PEGmwas added
to 1.25 × 106 glycopolymer-covered beads (resuspended in
150 μl PBS) and the resulting suspension was agitated on a
rotator at room temperature for 2 h. Afterwards the beads were
washed twicewith 500 μl of bead storage buffer, resuspended in
100 μl of bead storage buffer and stored as described above.2.5.3. Coupling of the heterobifunctional PEGs
After the standard activation procedure, bead pellets were
resuspended in 150 μl of biot-PEGm-NH2 solution (10 mg/ml,
0.1 M NaHCO3, pH 8.3), agitated in the dark on a rotator at
room temperature for 2 h. The obtained PEGylated beads with
biotin groups on their surfacewere applied for further coupling
to streptavidin and glycopolymers as described above.
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2.6.1. The regular procedure
The Bio-Plex 200 suspension array system (Bio-Rad Labo-
ratories, Hercules, CA, USA) is a multiplex analysis system that
permits the simultaneous analysis of up to 200 different
biomolecules in a single microwell plate. The constituents of
each well are drawn up into the flow-based Bio-Plex array
reader, which quantifies each specific reaction based on its
bead color using fluorescently labeled reporter molecules
specific for each target protein followed by Bio-Plex Manager
software data analysis. Antibody diluent (125 μl PBS, pH 7.2,
1% BSA (w/v), Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland) incorporating 2500 beads of each region per
well (50 μl/well) was added to a Bio-Plex Pro 96-well flat
bottom microplate (Bio-Rad Laboratories Inc., Hercules, CA,
USA). The plate was washed twice with washing buffer (PBS—
0.02% Tween-20 (v/v), pH 7.2) using a Bio-Plex Pro II Wash
Station (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Various anti-glycan antibody dilutions or human serum
samples, diluted to 1/40 (in accordance to (Pochechueva et
al., 2011a)), or antibody diluent alone as a negative control
were added to wells (in antibody diluent, 50 μl/well) and
vigorously agitated for 30 s on a microplate shaker before
incubation on a shaker with medium speed for 1 h at room
temperature in the dark. After incubation, the plate was
washed thrice with washing buffer using the Bio-Plex
Wash Station. Secondary antibodies (R-PE conjugated goat
anti-human IgM or IgG, 25 ng/well in antibody diluent,
50 μl/well) or antibody diluent alone as a negative control
were added and incubated for 30 min on the plate shaker in
the dark. The plate was washed thrice with washing buffer;
beads were resuspended and shaken for 30 s vigorously in
125 μl of washing buffer before being analyzed on the Bio-Plex
array reader. Data were acquired in real time, analyzing 100
beads by their median fluorescence intensity (MFI) using
computer software package (Bio-Plex Manager 5.1; Bio-Rad
Laboratories, Hercules, CA, USA). The technical cut-off of the
method, defined using a validation kit was 10 MFI. If not
otherwise denoted SGA experiments were performed with
triplicate experimental samples three times in an independent
manner.
2.6.2. Modiﬁcation of SGA protocol used for the detection of
biot-PEGm binding
As primary anti-glycan antibody anti-Pk rat monoclonal IgM
was applied (dilution of 1/100; incubation for 1 h), followed by
secondary biotinylated mouse anti-rat IgM (dilution of 1/1000;
incubation for 30 min) and streptavidin-R-PE (dilution of 1/200;
incubation for 10 min). All the other experimental details were
the same as described above.
2.7. Puriﬁcation of anti-glycan antibodies
Anti-A (Atri), anti-B (Bdi) and anti-αRha antibodies were
affinity purified from pooled plasma of blood group O
individuals as described previously (Obukhova et al., 2007;
Pochechueva et al., 2011a). Anti-P1, anti-LacNAc and anti-
3′-sulfo-LacNAc antibodies were affinity purified from ascites
(exudative fluid from peritoneal cavity) of an ovarian cancer
patient and processed by centrifugation at 3000 ×g for 15 minat 4 °C. Supernatant was aliquoted and kept frozen at−80 °C.
Thawed ascites (50 ml) was filtered through a 0.22 μm
filter (Millipore, Billerica, USA) and diluted in PBS (pH 7.4).
Pre-processed ascites was affinity purified against 10 ml of
equilibrated PBS glycan-PAA-Sepharose. A constant flow rate of
1 ml/min was controlled by an auxiliary pump (model EP-1
Econo Pump, Biorad, Hercules, USA). Protein content was
recorded by UV at 280 nm (BioLogic DuoFlow™Workstation,
Biorad, Hercules, USA). The column was washed with PBS
containing 0.05% (v/v) Tween 20, until no protein was
detected. Bound anti-glycan antibodies were eluted using
0.2 M TrisOH (pH 10.2) and neutralized by 2.0 M glycine HCl
(pH 2.5). Remaining eluted anti-glycan antibodies were con-
centrated using the Amicon® Ultra-0.5 centrifugal filter
(Millipore, Billerica, USA) and concentration was determined
spectrophotometrically at 280 nm. The following dilutions of
affinity purified antibodieswere used: anti-P1— 1/10 and 1/50;
and anti-Btri— 1/100, 1/200 and 1/500. All the other antibodies
were used in the dilution of 1/10.
Additional depletion of ascites fluid after removal of anti-P1
antibodies was performed as follows. After affinity purification
of anti-P1 antibodies, ascites fluid was additionally incubated
with P1-adsorbent, taken in a 1/1 ratio (v/v), for 1 h on a shaker
at RT, then centrifuged for 10 min, at 13,000 g. The supernatant
(diluted to 1:10with PBS, 1% BSA)was assayedwith P1-regular
and PEG-modified beads.
2.8. Statistical analysis
Statistical analysis was performed with GraphPad Prism 6
software using the repeated-measures ANOVA followed by
the Tukey posttest. Adjusted p-values b 0.05 were consid-
ered statistically significant.
3. Results and discussion
3.1. Design of various PEG-modiﬁcations
Expanding on the strategy of PEG linking we designed and
investigated several kinds of PEG-modifications in order to
mask sites on the glycobeads at which unspecific binding of
antibodies may occur: partial PEG substitutions with PEGs
of different lengths within end-biotinylated glycopolymers
(Scheme 1B); attachment of biotin-modified PEGs to presum-
ably unsaturated streptavidin binding sites next to coupling of
end-biotinylated glycopolymers (Scheme 1C); covalent bind-
ing of amino-functionalized biotin-PEGs (heterobifunctional
PEGs) directly onto the bead surface prior to glycopolymer
coupling (Scheme 1D).
3.2. PEG substitutions within the glycoprobes (Scheme 1B)
Glycoconjugates based on linear polyacrylamides (PAAs)
with side-attached carbohydrate groups are widely used in
bioanalytical research asmultivalent glycoprobes (Bovin, 1998,
2003). However, serum antibodies may bind not only to the
pendant glycan residues but also to the polymer backbone. The
latter effect can be reduced by the substitution of the side
groups (e.g. N-(2-hydroxyethyl)) within the non-glycosylated
monomer units by PEG. Three types of PEGs were used for this
purpose: “short” (m = 4, substitution rate −80%),
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see Glycopolymers with end-biotin group and Fig. 1). In
addition, two different glycopolymers were included: Btri
belongs to the ABO blood group system and served as a
“reference glycan”. P1 trisaccharide is our top candidate as
potential ovarian cancer marker (Pochechueva et al., 2011b;
Jacob et al., 2012).
The binding of corresponding affinity purified antibodies and
healthy donor plasma antibodies (analytes) to these different
PEGswith our regular (Scheme1A) Btri- and P1-glycoprobeswas
compared with SGA.
The results showed that the MFI values, representative for
antibody binding, were lower for all three PEGylated compared
to the regular glycopolymers. This was true for the Btri
(Fig. 3A) as well as the P1 (Fig. 3B) glycopolymers. Even more
interesting, the binding of the antibodies to both PEGylated
glycopolymers, i.e. Btri and P1, progressively decreased with
the increase of PEG chain length in a statistically significant
manner (p b 0.05) for all analytes. These results indicate that
(i) PEGylation reduces antibody binding to these glycopolymers
and that (ii) this decrease is PEG chain length-dependent.
This observation can unambiguously be explained by the
shielding of the glycan residues by the PEG molecules, which
is stronger with longer PEG chains attached to the polymer
backbone. However, this shielding effect is likely to affect
specific binding and presumably also unspecific binding of
the antibodies to these glycopolymers, and the distinction
whether or not unspecific binding of antibodies occurred to
non-glycosylated parts of polyacrylamide backbone was not
possible with these kinds of PEGylations.
To determine the potential contribution of unspecific
binding we assayed the beads modified with the regular or
with PEGylated P1-glycoprobes with native ascites fluid and
with ascites fluid depleted of anti-P1 antibodies. As expected
the results showed (ESM, Fig. 1) substantially lowerMFI values
in the depleted than in native ascites setting.More importantly,M
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settings, comparable to the setting for affinity purified and
plasma anti-glycan antibodies presented in Fig. 3B. The finding
that this PEG chain length-dependent decrease in binding
occurred in both settings, i.e. also in the native ascites, indicates
that these types of PEGs (different chain lengths) were not
sufficient to avoid unspecific antibody binding.
3.3. Biotinylated PEGs (biot-PEGm) bound to
glycopolymer-modiﬁed microbeads (Scheme 1C)
The next PEG modification considered was the attach-
ment of biotinylated PEGs (biot-PEG50 and biot-PEG280)
to glycopolymer pre-treated beads (see PEGs used for
glycopolymer and microbead modifications and Fig. 2A).
The idea was that these biot-PEGs may bind streptavidin
binding sites that may have been left unbound after the
antecedent coupling of the glycopolymers. We assayed the
binding of the analytes, i.e. three different human antibodies
(commercial anti-P1 monoclonal IgM antibody, affinity
purified anti-P1 antibodies, and plasma antibodies) to
regular and biot-PEGm-modified P1-conjugated beads.
Fig. 4A demonstrates that theMFI values for the regular and
the two biot-PEGm-modified P1-conjugated beads were compa-
rable for each of the analytes (differences in MFI values among
three types of beads were less than the inter-assay variability
(from 8.5 to 18.5%) previously described (Pochechueva et al.,
2011a)). This result indicates that the attachment of these two
biot-PEGm did not affect the binding of anti-glycan antibodies to
P1-beads. Possible explanations are that either all streptavidin
binding sites were saturated with biotinylated glycopolymer
prior to biot-PEGm coupling or the influence of non-target
binding to streptavidin was negligible.
To determinewhether streptavidin binding siteswere indeed
saturated by biotinylated glycopolymers and whether biot-PEGs
were able to block potentially remaining/unbound sites we0
5000
10000
15000
20000
25000
M
FI
P 1
P 1
- -P
E G
4 (
8 0
)
P 1
-P
E G
5 0
(5
)
P 1
-P
E G
2 8
0 (5
)
ibodies, antibodies in healthy plasma donors) is presented for the different
lamide (squares and triangles) glycopolymers Btri or P1. For the Btri setting
d O and for the P1 setting (B) affinity-purified anti-P1 antibodies and seven
ethods”). The binding was detected using R-PE labeled goat anti-human Ig
easurements performed in triplicates: identical analytes are connected by
in Tables 1 and 2 in the electronic Supplementary material.
49T. Pochechueva et al. / Journal of Immunological Methods 412 (2014) 42–52assayed the commercial monoclonal rat anti-Pk IgM antibody for
its binding to the regular and to the biot-PEGm-modified
P1-beads. Pk (also referred to as Gb3 or CD77) shares the
terminal Galα1–4Galβ1 motif with P1 trisaccharide, and the
anti-Pk antibody may thus cross-react to some extent with P1.
The secondary biotinylated anti-rat IgM antibody was used for
binding detection, followed by streptavidin-R-PE. The contribu-
tion of direct binding of the secondary biotinylated antibody to
the beads was determined in the absence of the primary anti-Pk
antibody.
The results are shown in Fig. 4B. For the regular P1
beads the MFI values were comparable, irrespective of the
presence or absence of the anti-Pk antibody. This indicates
that the secondary antibody binds directly to streptavidin on
these beads. In contrast, theMFI values in the absence of anti-Pk
antibodies were lower for both biot-PEGm (to a greater extent
with biot-PEG50). This demonstrates that direct binding of
secondary biotinylated antibody to streptavidin was almost
completely abolished (30-fold reduction) for biot-PEG50 and
intermediately (2-fold) reduced for biot-PEG280, suggesting
that the remaining streptavidin binding sites were almost
completely saturated by biot-PEG50 and partially saturated by
biot-PEG280.
These results indicate that (i) not all biotin-binding sites
on streptavidin were occupied by regular glycopolymers
initially, (ii) unspecific binding due to these remaining free
biotin-binding sites did not have any influence in our
standard experimental setup in the absence of secondary
biotinylated antibodies, (iii) the use of secondary biotinyl-
ated antibodies is feasible and still allows for the correct
detection of analyte binding in the case of end-pointM
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electronic Supplementary material. (B) Bar chart presenting the binding of the seco
regular P1 beads (black) and P1 bead modified with biot-PEG50 (gray) or biot-PEG280
antibodies) of the primary rat monoclonal anti-Pk IgM antibody (detailed exp
measurements performed in triplicates.addition of biot-PEG50 (or to a lesser degree of biot-PEG280)
to block the remaining free streptavidin binding sites, and
(iv) we can minimize the risk of unspecific binding often
caused by endogenous biotin in serum and cell and tissue
lysate samples by using biot-PEG50.
3.4. Microbead surface modiﬁcation with heterobifunctional
PEGs (Scheme 1D)
The heterobifunctional PEG23 and PEG60 (see PEGs used for
glycopolymer and microbead modifications and Fig. 2B for
structure and details) were coupled to the beads prior to
the anchoring of streptavidin and the immobilization of the
glycopolymers. In this setup the two versions of biot-PEGs-NH2
were bifunctional linkers between the bead and streptavidin.
The binding of human monoclonal anti-P1 antibodies as well as
plasma antibodies from healthy donors to modified beads was
assayed by SGA. The results (Fig. 5A) showed that binding of
monoclonal anti-P1 antibodies andplasma antibodies to all three
types of beads, i.e. regular P1-beads and P1-beads modified with
both heterobifunctional PEG, was comparable, indicating that
neither the bead modification with heterobifunctional PEGs in
general nor the PEG length affected antibody binding to P1. This
is in contrast to the PEGylated (different PEG chain lengths)
glycopolymers (Fig. 3) where the binding decreasedwith longer
PEG chains.
In order to explorewhether and howunspecific binding can
be detected we used anti-human IgG instead of anti-human
IgM as secondary antibodies for the detection of human
monoclonal anti-P1 IgM antibody binding to P1. In this setting
we assayed the binding to the regular P1-beads or the P1-beads1 2
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Fig. 5. (A) Comparison of the binding (given as MFI values) of analytes (n = 12: anti-P1 IgM antibody, four individual plasma samples; for dilutions see “Materials
and methods”) to regular P1 beads (spheres) and P1 beads modified with heterobifunctional PEGs: PEG23-P1 (squares) or PEG60−-P1 (triangles). The binding was
detected using R-PE labeled goat anti-human IgM (anti-P1 monoclonal human IgM) or R-PE labeled anti-human IgM and IgG (plasma samples). Each data point is
the mean of three independent MFI measurements in triplicates: identical analytes are connected by dotted lines. The mean MFI values and standard deviation for
each point are shown in Table 4 in the electronic Supplementary material. (B) Detection of non-target binding to regular P1 and heterobifunctional PEG-modified
beads. Data are the mean ± SD of three independent MFI measurements in triplicates as a function of increasing antibody dilution (as indicated) for P1-,
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50 T. Pochechueva et al. / Journal of Immunological Methods 412 (2014) 42–52modified with heterobifunctional PEGs by using progressively
higher dilutions of the anti-P1 IgM antibody. The results
(Fig. 5B) essentially showed that regular P1-beads exhibited
substantial unspecific binding which was notably substantially
reduced near to the technical cut-off level of the method
(approx. 10 MFI) with both heterobifunctional modified PEG
P1-beads (30-fold for PEG23 and 6-fold for PEG60). A decrease of
binding to regular P1-beads with progressively decreasing
anti-P1 IgM antibody concentrations was not observed. These
results suggest that commercial anti-P1 IgM antibodies may
contain traces of unspecific (heterophilic) antibodies of IgG
class which bind directly to the bead. We also performed a
similar experimentwith biot-PEG50- and biot-PEG280-modified
beads (see above), but did not observe any difference in
unspecific binding between these biotinylated PEG-modified
and regular P1-beads (data not shown). This indicates that only
bead modifications with heterobifunctional PEGs but not the
end-point addition of biot-PEG prevented unspecific binding of
non-target antibodies.
Because the nature of this unspecific IgG-mediated
binding was unknown we assayed P1-, PEG23-, and PEG60-P1
beads with several non-related anti-glycan antibodies of IgM
class (anti-Atri, anti-Bdi, anti-LacNAc, anti-3′-su-LacNAc, anti-
α-Rha) which we purified from human ascites fluid and
plasma. Regardless of the bead type we found that LacNAc
(Galβ1–4GlcNacβ) antibodies cross-reacted with P1 to some
extent (MFI from 300 to 450) whereas the other antibodies
cross-reacted to P1 only minimally (MFI of less than 100)
(ESM, Fig. 2). However, in a similar setting with the
respective IgG class antibodies (and also a commercial
monoclonal mouse anti-Pk IgG antibody) we found substan-
tial cross-reactivity of these IgG class antibodies to P1 with
the regular beads (MFI from 700 to 900) but not with the
heterobifunctional PEG P1-beads (MFIs below 200) (Fig. 6A).
These results indicate that the observed cross-reactivity
(unspecific binding) may be largely attributed to the IgG classof the anti-glycan antibodies. For comparison the binding of the
monoclonal anti-Pk IgG antibody to the P1-beads is included,
showing the extent of the cross-reactivity of the anti-Pk
antibody to P1 (Fig. 6A). The cross-reactive binding of anti-Pk
IgG to P1 may, even with monoclonal antibodies, not be
surprising, because Pk and P1 share the same terminal
disaccharide motif. The vast number of naturally occurring
anti-glycan antibodies generally are not monospecific and
exhibit some degree of polyreactivity: they are able to
recognize more than one glycan structure but bind them with
differing affinities. The latter may serve to “fine tune” their
actions in vivo (Schwartz-Albiez, 2012). These results also
indicate that this IgG class-dependent cross-reactivity can be
reduced by the introduction of PEGs, and this is considered
important for the accurate detection of analytes in particular in
an artificial array system as the SGA.
In order to determine the contribution of non-target
binding we assayed P1-, PEG23-, and PEG60-P1 modified beads
with fetal calf serum-derived and presumably heterophilic
antibodies. The results (Fig. 6B) demonstrate that no
substantial binding to all three types of beads was observed
for IgM (MFI of around 20) whereas some binding (MFI of
around 500) was detected for IgG for the regular P1-beads.
This observation is in concordance to the previous experi-
ments (Figs. 5B and 6A). These IgG signals were reduced for
the PEG60-P1 beads to about 100 MFI and for the PEG23-P1
beads to 15 MFI.
In summary, unspecific binding was observed almost
exclusively when IgGs, but not IgMs were applied as
glycan-binding antibodies or as secondary detection antibod-
ies. These data seem to be consistent with existing evidence
regarding anti-glycan antibodies. It is known that naturally
occurring anti-glycan antibodies are predominantly of IgM
class and are produced by CD5 positive B1 cells expressing a
distinct pattern of surfacemarkers, but not conventional B cells
(Viau and Zouali, 2005; Vollmers and Brandlein, 2009; Griffin
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anti-glycan IgMs appear to be highly specific in terms of affinity
distinctions. Specific recognition of certain glycan structure
strongly depends on its natural molecular context (Bovin,
2013). Pentameric IgMs have ten Fab regions and therefore
possess a theoretical valency of 10. Multivalent recognition is
very important for glycan–protein interaction, providing stable
and affine binding to multiple oligosaccharide structures. On
the contrary, IgGs are only divalent, their interactions with
glycans may be weaker that is why this antibody class is
typically not ascribed to recognize glycans in nature. Due to the
same reasons IgGs may be more predisposed to unspecific
binding than IgMs upon profiling with glycoarrays.
To further exploit the possibility to reduce anti-glycan
antibody cross-reactivity by using heterobifunctional PEGs,
we linked PEG23 and PEG60 to the bead surface, coupled Pk
trisaccharide to these beads, and compared the binding of
monoclonal human anti-P1 IgM either to P1-coupled beads or
to Pk-coupled beads (without or with heterofunctional PEGs)
as a function of the antibody dilution (Fig. 7). The results
showed that the binding of the anti-P1 IgM antibodies,
regardless of the dilution, to Pk-beads was several-fold
lower than to P1-beads, indicating that indeed anti-P1
antibodies bind to Pk trisaccharide with much lower affinity
than P1 trisaccharide. The binding signals were even further
lowered (about 2-fold) with both kinds of heterobifunctional
PEGs.a n
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Fig. 7. Bar graph presenting the binding of anti-P1 monoclonal human IgM to
regular and heterobifunctional PEG23/PEG60-modified Pk-beads. The binding
to regular P1-beads is given for comparison. Detection with R-PE labeled
goat anti-human IgM. Data are the mean ± SD of three independent MFI
measurements in triplicates.4. Conclusion
In this study we designed and evaluated various kinds of
PEG-modifications, exploiting unique chemically synthesized
end-biotinylated glycopolymer capture molecules in combi-
nation with a simple and affordable PEG-linking, to optimize
the current version of our previously “in-house” developedSGA in order to reduce the experimental background
(essentially unspecific and non-target binding) of this
glycan-based assay. This background reduction may mini-
mize the risk of occurrence of false-positive/negative results
and may improve the diagnostic performance (increased
sensitivity and specificity) of SGA. The following conclusions
may be drawn from the findings: (i) The most significant
decrease of background binding was achieved when PEG
molecules bearing two functional groups, biotin and amine
(hence heterobifunctional), were covalently attached directly
to microbeads. This modification may be beneficial because it
decreases “experimental noise” at low detection signals and
does not compromise specific binding of the cognate anti-
52 T. Pochechueva et al. / Journal of Immunological Methods 412 (2014) 42–52glycan antibodies. Interestingly, the shorter version of these
two heterobifunctional PEGs, biot-PEG23-NH2, exhibits a
more pronounced repelling effect, namely the capacity to
block binding of non-target antibodies, than the respective
longer version and therefore may preferably be used in an
advanced version of SGA. (ii) The end-point addition of
biot-PEG50 can be used to repel unspecific binding caused by
endogenous biotin potentially present in the analyte (e.g. plasma
samples) or in secondary antibody samples and can be easily
combined with bead surface PEGylation. (iii) A considerable
extent of unspecific binding can be attributed to the IgG class of
the antibodies whereas the contribution of IgM class antibodies
to unspecific binding signals is low. It is therefore recommended
to use IgM class rather than IgG class antibodies in glycan-based
immunoassays. (iv) Background binding was not reduced when
glycopolymers were PEG-modified at their side-chains, possibly
because the PEG-chains that are attached to polyacrylamide
backbone of glycopolymer preclude specific binding of anti-
glycan antibodies to the glycan epitopes. Taken together, the
combination of the appropriate PEG-modifications, i.e. the bead
modification with PEG23 and the end-point addition of biot-
PEG50 is a promising advancement in the optimization of the
current version of our SGA. These or similar modifications
probably could be also recommended to be included in
experimental protocols of related bead-based immunoassays
for the improvement of their diagnostic performance.
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